FDA-approved Nrf2 activators, Tecfidera and Skyclarys for patients with multiple sclerosis and Friedreich's ataxia, respectively, are non-specific alkylating agents exerting side effects. Nrf2 is under feedback regulation through its target gene, transcriptional repressor Bach1.
Friday, November 10, 2023
Emerging small molecule inhibitors of Bach1 as therapeutic agents: Rationale, recent advances, and future perspectives
Hushpulian DM, Kaidery NA, Dutta D, Sharma SM, Gazaryan I, Thomas B. Emerging small molecule inhibitors of Bach1 as therapeutic agents: Rationale, recent advances, and future perspectives. Bioessays. 2023 Nov 2:e2300176. doi: 10.1002/bies.202300176. Epub ahead of print. PMID: 37919861.
Subscribe to:
Posts (Atom)
